TSPO Ligands: Accurate, Inclusive Neuroinflammation Imaging
High Accuracy Agents for Imaging Neuroinflammation
Tags: The University of Sydney, Australia, Healthcare & Lifesciences
This innovation introduces novel Translocator Protein 18kDa (TSPO) ligands for PET imaging that overcome limitations of existing neuroinflammation diagnostics by exhibiting high affinity and sensitivity. These ligands are effective across all genetic variants of TSPO, enabling accurate imaging for conditions like Multiple Sclerosis, Alzheimer's, Parkinson's Disease, and Traumatic Brain Injury. Applications include improved diagnostic imaging, disease progression monitoring, and evaluation of anti-inflammatory treatments. The technology enhances personalized and inclusive healthcare by addressing a broader patient population. Two patent families (PCT/AU2023/051173 and AU2023903723) filed by the University of Sydney protect the intellectual property of this breakthrough.
IP Type or Form Factor: Patent Pending; Material; Software & Algorithm
TRL: 3 - proof of concept with needs validated
Industry or Tech Area: Diagnostics & Screening; Healthcare Provider
